Why did my GLP-1 plateau and what should I do next? The plateau is the most predictable event in GLP-1 therapy and the least well explained. You started on semaglutide or tirzepatide and the scale moved steadily for months. Then, somewhere in month five or eight, it stopped. The instinct that follows is usually one of two bad options: escalate the dose on your own or quit the medication entirely. Both are wrong. This article is the clinical explanation we give our own patients.
- Plateaus are expected physiology. Energy needs fall as you lose weight and the same dose produces a smaller deficit.
- A true plateau is four to six weeks of no change on a consistent routine, not two bad weeks on the scale.
- Dose escalation is often the wrong lever. Protein, resistance training, sleep and stress come first.
- We titrate to the lowest dose that gets the most result and our fee never changes with the dose.
- The quarterly Biomarker Audit reads muscle, metabolic and inflammatory markers alongside the scale, because the scale is not the goal.
Why the scale stops
The physiology is not mysterious. As you lose weight, your resting energy expenditure falls, you burn fewer calories moving the smaller body through the day and the appetite suppression that was producing a large deficit now produces a smaller one. The medication is working the same way it always did. The math underneath it changed.
In the pivotal trials this pattern was visible across whole populations. In STEP-1, semaglutide produced an average weight loss of roughly fifteen percent over 68 weeks and the curve slowed for most participants in the second half even as it continued. In SURMOUNT-1, tirzepatide produced average losses up to roughly twenty-two percent at the highest dose over 72 weeks with the same flattening toward the end. Individual results vary and the trial averages are averages, but the shape of the curve, fast early, slower late, is what the data actually shows.
What a true plateau is and what it is not
Before anything else, the definition. Water, glycogen and digestive content swing the scale by several pounds in either direction on a timescale of days and women see a larger monthly cycle on top of that. A true plateau is roughly four to six weeks of no change while your food, activity and dose have stayed consistent. Anything shorter than that is noise and treating noise with a dose change is the classic way people end up on more medication than they need.
The second question is what stopped moving. The scale can pause while body composition keeps improving, especially when resistance training has begun, because muscle is denser than fat and the mirror and the measurements move while the scale does not. This is one reason the Biomarker Audit reads more than weight, tracking the metabolic and inflammatory markers that show whether the therapy is still delivering benefit beneath a static number.
The plateau question is not how do I raise the dose. It is what has changed in the math and which lever moves it with the least medicine.
What actually moves it
The levers below are ordered by how often they resolve the plateau without any dose change.
Protein intake. GLP-1 medications suppress appetite so effectively that many patients drift below their protein target and both muscle preservation and satiety suffer. Getting protein back to target, spread across the day, is the single most common fix in our clinical experience.
Resistance training. Two to three sessions a week protect lean mass during weight loss and raise resting energy expenditure, which directly attacks the mechanism of the plateau. It is the lever with the strongest evidence and the one most often skipped.
Sleep and stress. Poor sleep and elevated cortisol blunt weight loss independently of diet and exercise and both are common enough in the plateau window that they belong on the checklist before any dose conversation.
The dose itself. Only after the above is the dose the right lever and even then the honest framing matters. A higher dose of a branded medication costs more at the pharmacy, because the pharmacy bills by dose at its own price with no markup from us. That is one reason our clinical protocols titrate to the lowest effective dose that achieves the most result and why the flat fee never changes no matter where the dose lands. Our revenue is identical at the lowest dose and the highest, so the titration decision has no profit motive on our side.


What not to do
Do not buy compounded semaglutide or tirzepatide because the branded price at a higher dose stings. Compounded copies are not FDA-approved, they vary in potency and purity and the savings come with a risk profile the branded product does not carry. We prescribe branded, FDA-approved medication only, Wegovy, Zepbound, Ozempic, Mounjaro or Wegovy Tablets and Foundayo where clinically appropriate and we never facilitate compounded copies.
Do not stop the medication abruptly without a plan, either. Weight regain after discontinuation is well documented in the trials and if the plateau has you questioning the whole therapy, that conversation belongs with the clinician who has your quarterly data, not with the scale.
What the quarterly audit changes about this conversation
In a per-visit system, the plateau conversation happens whenever you can afford a visit, on whatever data the clinic happens to have, which is often none. In the membership, the conversation happens on schedule with a full panel behind it. Every 90 days the Biomarker Audit reads HbA1c, fasting insulin, the lipid panel, ApoB, Lp(a), hs-CRP, thyroid and the CBC, alongside your weight trend and the clinician titrates against that whole picture rather than a single number.
This is where the Stability-Seeking patient finds the model built for them. The goal is the lowest dose that gets the most result, reassessed quarterly and the fee is the same $299 regardless of what the assessment concludes. If your dose goes down, our revenue does not change. If it goes up, our revenue does not change. What changes is what your labs say.
What the membership costs, stated plainly
The Cardiometabolic Optimization Membership is one flat $299 per month covering the clinical relationship and four quarterly Biomarker Audits a year. It starts with a two month commitment paid as a single $598 hold covering the first two months together, charged only once a clinician accepts you into care. If no clinician can accept you, the hold is released and you are never charged. Once accepted, the first two months are non-refundable. From month three the membership is month to month and you can cancel anytime.
Medication is a separate charge and it never flows through us. Any prescription is written to the pharmacy you choose and billed by that pharmacy at its own price. GoodLife Health sets nothing, sees nothing and takes nothing on that transaction. There is no molecule upcharge and no dose upcharge, ever. One flat fee for the doctor. Zero markup on the medicine. The eligibility check is free and takes a few minutes.
Frequently Asked Questions
Why did my GLP-1 plateau?
Plateaus are expected physiology. As you lose weight your energy needs fall and the body adapts, so the same dose produces a smaller deficit. In the STEP-1 and SURMOUNT-1 trials weight loss continued over the full trial window, but the rate slowed for most participants as the body adapted.
Does a plateau mean I need a higher dose?
Often no. Many plateaus resolve with changes in protein intake, resistance training, sleep and stress before any dose change. A higher dose has real tradeoffs in side effects and cost and the honest clinical question is whether the plateau reflects dose, behavior or physiology.
How long should a plateau last before acting?
A true plateau is roughly four to six weeks of no change on a consistent routine. Normal water and glycogen fluctuations mask fat changes for shorter windows, so acting sooner than that usually chases noise.
What actually moves the scale after a plateau?
The same levers that prevent muscle loss. Protein at target, resistance training two or three times a week, sleep and stress management and where clinically appropriate a dose adjustment under a physician's care.
Will a higher dose cost more?
At GoodLife Health our fee does not change with dose. The pharmacy bills the medication separately at pharmacy cost with no markup and higher doses of branded medication cost more at the pharmacy than lower ones, which is one reason we titrate to the lowest effective dose.
How does GoodLife Health handle plateaus?
The quarterly Biomarker Audit tracks weight, body composition proxies and metabolic markers together and the clinician titrates to the lowest dose that gets the most result, rather than escalating by default.
How much does the membership cost?
One flat $299 per month covering the doctor and four quarterly lab audits a year, after a two month start paid as one $598 charge covering the first two months together. Medication is billed by your pharmacy separately at pharmacy cost with zero markup.
One last thing
The plateau is not the medication failing and it is not you failing. It is the math changing under the therapy and the response that works is the one made on full quarterly data by a clinician whose income does not depend on the answer. That is the model and the eligibility check is where it starts.
Related Guides
- What a Biomarker Audit includes
- Medical weight loss
- Cardiometabolic Optimization: the definitive guide
- Direct primary care explained